Independent Peptide Analysis
Evidence-based analysis, vendor accountability, and honest guidance in a market flooded with marketing claims. No vendor sponsorship. No pay-for-play reviews.
12 peptides came off Category 2 in April, but June brought a stacked FDA advisory panel, agency scientists warning against approval, and new warning letters.
Independent analysis of the FDA peptide reclassification. 12 peptides came off Category 2 in April. The July 23-24 PCAC vote decides what happens next.
FDA still hasn't published peptide reclassification 29 days after RFK announcement. NPR coverage drives new audience. SAFE Drugs Act bill text on Congress.gov.
Independent guide to buying BPC-157 in 2026. Grey-market vendors rated, compounding pharmacy options, and what the FDA reclassification means for access.
Guide to legal semaglutide access in 2026. FDA-approved Ozempic, Wegovy, Oral Wegovy ($149/mo), and why grey-market semaglutide should be avoided.
Oral BPC-157 vendors rated on transparency, third-party testing, value, and regulatory compliance. Updated quarterly.
Ratings reflect our independent analysis. Vendors cannot pay to improve their scores. See our methodology.
Evidence-rated profiles for every major peptide. What the research shows, what it doesn't, and what vendors won't tell you.
Weekly analysis of the peptide market: regulatory changes, vendor evaluations, research updates, and the news that matters. Zero vendor influence.